GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Shiller PE Ratio

Albireo Pharma (FRA:BDQM) Shiller PE Ratio : (As of Jun. 09, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Albireo Pharma Shiller PE Ratio Historical Data

The historical data trend for Albireo Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Shiller PE Ratio Chart

Albireo Pharma Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Albireo Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Albireo Pharma's Shiller PE Ratio

For the Biotechnology subindustry, Albireo Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Albireo Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albireo Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Albireo Pharma's Shiller PE Ratio falls into.



Albireo Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Albireo Pharma's E10 for the quarter that ended in Sep. 2022 is calculated as:

For example, Albireo Pharma's adjusted earnings per share data for the three months ended in Sep. 2022 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=-1.939/125.2265*125.2265
=-1.939

Current CPI (Sep. 2022) = 125.2265.

Albireo Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201212 -5.944 96.871 -7.684
201303 -8.569 98.209 -10.926
201306 -15.009 98.518 -19.078
201309 1.122 98.790 1.422
201312 -2.628 98.326 -3.347
201403 -6.290 99.695 -7.901
201406 -3.312 100.560 -4.124
201409 -2.328 100.428 -2.903
201412 -4.866 99.070 -6.151
201503 -4.990 99.621 -6.273
201506 -3.208 100.684 -3.990
201509 -1.390 100.392 -1.734
201512 -1.377 99.792 -1.728
201603 -2.425 100.470 -3.023
201606 -1.335 101.688 -1.644
201609 -0.668 101.861 -0.821
201612 -12.504 101.863 -15.372
201703 -0.991 102.862 -1.206
201706 -0.765 103.349 -0.927
201709 -0.612 104.136 -0.736
201712 -0.439 104.011 -0.529
201803 -0.122 105.290 -0.145
201806 -1.044 106.317 -1.230
201809 -1.003 106.507 -1.179
201812 -1.178 105.998 -1.392
201903 -1.230 107.251 -1.436
201906 -1.195 108.070 -1.385
201909 -1.571 108.329 -1.816
201912 -0.513 108.420 -0.593
202003 -2.018 108.902 -2.321
202006 -1.225 108.767 -1.410
202009 -1.664 109.815 -1.898
202012 -1.069 109.897 -1.218
202103 -1.924 111.754 -2.156
202106 -1.577 114.631 -1.723
202109 2.465 115.734 2.667
202112 -0.504 117.630 -0.537
202203 -1.989 121.301 -2.053
202206 -1.930 125.017 -1.933
202209 -1.939 125.227 -1.939

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Albireo Pharma  (FRA:BDQM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Albireo Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Albireo Pharma (FRA:BDQM) Business Description

Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines